A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)

PREG-MS: New England MS Pregnancy Registry

NCT03368157 ·Status: COMPLETED

Pregnancy Cohort in Multiple Sclerosis (MS)

NCT05010902 ·Status: RECRUITING

Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy

NCT07149662 ·Status: NOT_YET_RECRUITING

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

NCT06681623 ·Status: RECRUITING

Kesimpta Pregnancy and Infant Safety Study Using Real World Data

NCT06156683 ·Status: RECRUITING

A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

NCT05064436 ·Status: TERMINATED ·Phase: PHASE1

Safety of Exposure to Natalizumab During Pregnancy

NCT05209815 ·Status: COMPLETED

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

NCT05688436 ·Status: RECRUITING

Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)

NCT00168714 ·Status: COMPLETED

A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis

NCT00097188 ·Status: COMPLETED ·Phase: PHASE2

LEMTRADA Pregnancy Registry in Multiple Sclerosis

NCT03774914 ·Status: TERMINATED

Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis

NCT03046251 ·Status: COMPLETED ·Phase: PHASE4

Study Evaluating CCI-779 in Relapsing Multiple Sclerosis

NCT00228397 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

NCT07220252 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

NCT02738775 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504 ·Status: RECRUITING ·Phase: PHASE3

A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants

NCT06133049 ·Status: ACTIVE_NOT_RECRUITING

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

NCT01864148 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

NCT07211633 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

NCT06735248 ·Status: RECRUITING ·Phase: PHASE2

A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)

NCT00239655 ·Status: TERMINATED ·Phase: PHASE2

A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis

NCT00087529 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

NCT03277261 ·Status: COMPLETED ·Phase: PHASE3

TMP001 in Relapsing-remitting Multiple Sclerosis

NCT02686788 ·Status: COMPLETED ·Phase: PHASE2

Biogen Multiple Sclerosis Pregnancy Exposure Registry

NCT01911767 ·Status: COMPLETED